SCHEMBL2368085

SCHEMBL2368085

CCOC(=O)C(C#N)=C(C)c1ccc(F)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.50
ALDH1A1 P00352 4/20 0.50
KMT2A Q03164 6/20 0.47
MEN1 O00255 5/20 0.47
LMNA P02545 3/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
KDM4E B2RXH2 3/20 0.44
GAA P10253 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CASP3 P42574 1/20 0.43
TRPV1 Q8NER1 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
THRB P10828 1/20 0.41
ALOX12 P18054 1/20 0.41
HPGD P15428 1/20 0.41
CES2 O00748 1/20 0.41
ACHE P22303 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368081 1.00 MAPT (0.50) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL11138250 0.92 MAPT (0.46) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL11138252 0.92 MAPT (0.46) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL1554071 0.88 DHODH (0.44) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL1554070 0.88 DHODH (0.44) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL9726685 0.87 MAPT (0.51) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL20551554 0.85 MAPT (0.56) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL20551552 0.85 MAPT (0.56) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL1554676 0.85 MAPT (0.47) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL1554675 0.85 MAPT (0.47) MAPTALDH1A1KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193215-B2 Thieno[2 3-b]pyridines as potassium channel inhibitors XENTION LIMITED (GB) 2012-06-05 US disclosed
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1879899-B1 THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-08-04 EP disclosed
US-20100041695-A1 Thieno[2,3-b]pyridines as Potassium Channel Inhibitors XENTION LIMITED (GB) 2010-02-18 US disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041695-A1 Thieno[2,3-b]pyridines as Potassium Channel Inhibitors SCN8A, SCN1B, SCN2B MAPT 4755/4885ALDH1A1 3155/4885KMT2A 2561/4885
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 MAPT 2978/4885ALDH1A1 247/4885KMT2A 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.